Aardvark Therapeutics (NASDAQ:AARD) Given New $19.00 Price Target at Royal Bank Of Canada

Aardvark Therapeutics (NASDAQ:AARD) had its target price reduced by Royal Bank Of Canada from $20.00 to $19.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other analysts have also recently issued reports on the company. Wall Street Zen cut Aardvark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. HC Wainwright started coverage on shares of Aardvark Therapeutics in a research report on Monday, June 30th. They set a “buy” rating and a $40.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.80.

Aardvark Therapeutics Price Performance

AARD opened at $11.26 on Thursday. The business has a 50 day moving average price of $12.52. Aardvark Therapeutics has a 1-year low of $4.88 and a 1-year high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last announced its earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.14).

Institutional Trading of Aardvark Therapeutics

Several hedge funds have recently modified their holdings of AARD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Aardvark Therapeutics in the 2nd quarter valued at about $42,000. Walleye Capital LLC bought a new stake in Aardvark Therapeutics during the 1st quarter worth approximately $88,000. New York State Common Retirement Fund bought a new stake in Aardvark Therapeutics in the 2nd quarter valued at $99,000. Goldman Sachs Group Inc. acquired a new stake in Aardvark Therapeutics in the 1st quarter valued at approximately $153,000. Finally, Geode Capital Management LLC boosted its holdings in Aardvark Therapeutics by 129.7% during the second quarter. Geode Capital Management LLC now owns 136,927 shares of the company’s stock worth $1,851,000 after purchasing an additional 77,327 shares during the last quarter.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.